Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GX-P1 in Healthy Male Volunteers
NCT04298749Phase 1Completed
- Sponsor
- Genexine
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Fc-fusion protein, Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GX-P1 in autoimmune diseases (3 arms), sponsored by Genexine. Primary endpoint: Safety and tolerability as measured by Adverse Events up to 8 weeks. Started Aug 2020; status: completed.
02
Drugs
GX-P1
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT04298749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298749.